IL2 and renal carcinoma: We believe this approach is not optimal especially in patients with renal cancer as durable remissions are rarely achieved with TKI therapy, and the patient’s performance status is more likely to decline with each successive systemic treatment, thus the opportunity to use IL-2 can be lost.